Threshold Pharmaceuticals Inc.'s stock took a walloping after news that the FDA had put the Phase II program with TH-070 (lonidamine) for benign prostatic hypoplasia on partial clinical hold because of liver enzyme abnormalities, and Threshold stopped dosing in the European Phase III trial, as well. (BioWorld Today)

Ariad Pharmaceuticals Inc.'s stock jumped after news of a victory valued at about $65.2 million in its patent lawsuit against Eli Lilly and Co. - though Lilly plans first to ask the judge to set aside the jury's verdict regarding Evista and Xigris and then to appeal, if necessary. (BioWorld Today)